Teriparatide

What is Teriparatide?

Teriparatide is a recombinant version of the first 34 amino acids of human parathyroid hormone, PTH(1-34). Sold as Forteo, it is an FDA-approved prescription drug for osteoporosis in people at high risk of fracture. It stands out in this library because it is a fully approved medicine with strong human trial data, not a research compound. Unlike drugs that mainly slow bone loss, teriparatide is anabolic: it actively builds new bone.

How Teriparatide works

Parathyroid hormone has a paradoxical effect on bone that depends entirely on timing. Continuously high PTH, as in overactive parathyroid glands, drives bone breakdown. But short, once-daily pulses of PTH activation flip the balance the other way, stimulating bone-forming osteoblasts more than bone-resorbing osteoclasts. Teriparatide exploits that difference. A single daily injection produces a brief spike of PTH-receptor activation, which over months yields net new bone, greater bone mineral density, and stronger bone architecture.

What the research shows

Teriparatide has the kind of evidence most peptides never get. In the pivotal Fracture Prevention Trial of postmenopausal women who already had vertebral fractures, daily teriparatide reduced the risk of new vertebral fractures by about 65 percent and nonvertebral fragility fractures by about 53 percent compared with placebo, alongside clear gains in spine and hip bone density, over a median follow-up of roughly 19 months. That trial and later studies established it as a genuine anabolic therapy. Its history also carries a cautionary chapter: high, near-lifetime doses in rats produced osteosarcoma, a bone cancer, which shaped its early labeling.

Dosage and how it is used

The approved dose is 20 micrograms injected subcutaneously once daily, delivered from a prefilled multi-dose pen. It is a prescription medicine used under a clinician's supervision, typically for people with severe osteoporosis or high fracture risk. Originally the label capped total use at two years, but the FDA removed that strict lifetime limit in 2020. This is not a self-directed protocol; dosing and duration are medical decisions.

→ How to reconstitute Teriparatide: calculator, units to draw & storage

Side effects and safety

Common side effects are usually mild: dizziness, leg cramps, nausea, and occasional transient rises in blood calcium. The more notable safety story is the osteosarcoma question. That worry came from rats given high doses for most of their lives, and long-term human observational data did not show the same signal, so in 2020 the FDA removed both the boxed warning and the two-year lifetime cap. It is still avoided in people at higher baseline risk of bone cancer, such as those with Paget's disease or prior skeletal radiation.

• FDA-approved with extensive human trial data, including large fracture-reduction results.
• The rodent osteosarcoma finding led to a boxed warning that the FDA removed in 2020.
• A prescription drug used under medical supervision. Verify current status independently.

Frequently asked questions

References

• Neer RM et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med, 2001.
• Krege JH et al. Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates. JBMR Plus, 2022.